Extrahepatic metabolism of ibrutinib

Ibrutinib is a first-in-class Bruton’s kinase inhibitor used in the treatment of multiple lymphomas. In addition to CYP3A4-mediated metabolism, glutathione conjugation can be observed. Subsequently, metabolism of the conjugates and finally their excretion in feces and urine occurs. These metabolites...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Invest New Drugs
Asıl Yazarlar: Rood, Johannes J. M., Jamalpoor, Amer, van Hoppe, Stephanie, van Haren, Matthijs J., Wasmann, Roeland E., Janssen, Manoe J., Schinkel, Alfred H., Masereeuw, Rosalinde, Beijnen, Jos H., Sparidans, Rolf W.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer US 2020
Konular:
Preclinical Studies
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7851014/
https://ncbi.nlm.nih.gov/pubmed/32623551
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-020-00970-x
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller